Clinical trial
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
NCT05452772 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
- Lead sponsor
- Johns Hopkins University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 1, 2023
- Completion date
- May 31, 2027
- Enrollment
- 66 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.